Datasea partners with Linghang for brain-computer interface technology By Investing.com

Datasea Inc. has announced a strategic partnership with Nanjing Linghang Intelligent Aviation Technology Co., Ltd. to integrate its acoustic enhancement technologies into non-invasive brain-computer interface (BCI) systems and healthcare robots. This collaboration aims to address challenges in EEG signal stability and decoding accuracy, focusing on applications in rehabilitation and healthcare. The global BCI market is projected to exceed $15-20 billion by 2030, with non-invasive BCI technologies expected to be the fastest-growing segment, offering significant market potential despite Datasea's current thin gross profit margins and unprofitability.

Original reporting
Published Jan 5, 2026, 3:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jan 5, 2026, 4:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$DTSS
Bullish
medium confidence
Mentioned
$DTSS
Relevance
6/10
AlphAI data visualization · based on Investing.com Australia
Decision brief

The 30-second read

$DTSSBullishMed
01

Why it matters

The collaboration could enhance Datasea's technological capabilities and market positioning, potentially leading to stock appreciation.

02

Market read

The BCI market is projected to grow significantly, with non-invasive solutions leading the segment, offering substantial growth opportunities for involved companies.

03

What to watch

Potential regulatory hurdles and competition in the BCI space could affect outcomes.

Relevance 6/10Timing: Immediate

Background

Datasea is expanding into neurotechnology through partnerships, aiming to leverage advancements in brain-computer interfaces for healthcare applications.

Company-level read

Ticker impact

$DTSSBullishMedium confidence
Context

The news involves Datasea Inc. (DTSS), highlighting a strategic partnership in brain-computer interface technology.

Expected impact

Moderate upward movement in the short to medium term.

Evidence & confidence

The collaboration aligns with growing industry trends in BCI technology, but Datasea's current profitability issues temper the impact.

Market effects

Potential uplift in the neurotechnology and healthcare robotics sectors.

Limited to regional markets with active biotech and tech sectors.

Moderate, given the global growth projection of the BCI market.

Counterpoint

The partnership's impact may be overestimated; technological challenges and Datasea's financial health could limit stock appreciation.

Key entities

  • Datasea Inc.

    A technology company focusing on IoT, AI, and neurotechnology.

  • Linghang

    Nanjing Linghang Intelligent Aviation Technology Co., Ltd., specializing in acoustic and aerospace technologies.

Related articles

$DTSSMed

Datasea Announces FDA Registration and Device Listing for NeuroVibe Acoustic BCI Biofeedback System as a Class II 510(k)

Datasea Intelligent Technology Ltd. (NASDAQ: DTSS) said its China VIE, Shuhai Jingwei, completed FDA establishment registration and device listing for the NeuroVibe acoustic biofeedback system (NV-02, NV-03). The devices were listed as Class II 510(k)-exempt biofeedback medical devices under FDA product code HCC. Datasea said this supports U.S. commercialization planning; listing is not FDA approval.

$EQNRMed

Galp Energia and Equinor Get Offshore Brazilian Oil Block

Galp Energia and Equinor have been awarded an offshore oil block in Brazil's Santos Basin. Galp will own 30% of the Rodocrosita block, with Equinor operating the remaining 70%. The companies may explore synergies with the adjacent Bacalhau project, which is ramping up production and will contribute 40,000 barrels per day to Galp once fully operational.

$PINSMed

Pinterest (PINS), Why Is It Back In The Spotlight?

Pinterest (PINS) appointed Amazon's James Dibbo as its new CFO. The company's stock has shown mixed performance, with a recent 7-day return of 7.52% but a 1-year return of -36.11%. Analysts have varying views on its valuation, with some seeing it as undervalued at $20.31 per share compared to a fair value estimate of $29.05, while others note its high P/E ratio of 46.2x.